merck & co. inc. (6MK:Frankfurt)
Transactions by MERCK & CO. INC. (6MK) in the last 6 months
AstraZeneca LP acquired KBI, Inc. from Merck & Co. Inc. (NYSE:MRK) for approximately $420 million in cash on June 30, 2014. Of this amount, $91 million was paid at the closing and $327 million reflects an estimate of the fair value of Merck’s interest in Nexium and Prilosec. This portion of the purchase price, which is subject to a true-up in 2018 based on actual sales from closing in 2014 to June 2018, was deferred and will be recognized over time in Other (income) ...
Merck & Co. Inc. (NYSE:MRK) entered into a definitive agreement to acquire Idenix Pharmaceuticals Inc. (NasdaqGS:IDIX) from T. Rowe Price Associates, Inc., Nomura International plc, Brookside Capital Management, LLC, The Baupost Group, LLC and other shareholders for $3.84 billion in cash on June 8, 2014. Under the terms of the agreement, Merck will pay $24.5 per share. Under the terms of the agreement, Merck, through a subsidiary, will initiate a tender offer to acquire ...
MPM BioVentures I, L.P.
Nomura International plc
Novartis Pharma AG
Novartis Venture Funds
T. Rowe Price Associates, Inc.
The Baupost Group, LLC
|3M Co||$160.16 USD||+0.80|
|Bayer AG||€117.17 EUR||+3.34|
|Gilead Sciences Inc||$100.58 USD||-0.01|
|Pfizer Inc||$30.45 USD||+0.01|
|Roche Holding AG||SFr.289.90 CHF||+1.60|
|View Industry Companies|